IGF-BP7

• Description:

  IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 257 amino acid residues.

• Synonyms:

  IGFBP7; AGM; PSF; TAF; FSTL2; IBP-7; MAC25; IGFBP-7; RAMSVPS; IGFBP-7v; IGFBPRP1

• NCBI Gene ID:

  3490

• UniProt:

  Q16270

• Accession Number:

  NP_001544.1

• Accession Number mRNA:

  NM_001553

• Chromosomal Location:

  4q12

• Reactivity:

  Human

• Cross Reactivity:

  Human

• Sequence:

  SSSDTCGPCE PASCPPLPPL GCLLGETRDA CGCCPMCARG EGEPCGGGGA GRGYCAPGME CVKSRKRRKG KAGAAAGGPG VSGVCVCKSR YPVCGSDGTT YPSGCQLRAA SQRAESRGEK AITQVSKGTC EQGPSIVTPP KDIWNVTGAQ VYLSCEVIGI PTPVLIWNKV KRGHYGVQRT ELLPGDRDNL AIQTRGGPEK HEVTGWVLVS PLSKEDAGEY ECHASNSQGQ ASASAKITVV DALHEIPVKK GEGAEL

• Endotoxin:

  < 0.1 ng/µg of protein (< 1EU/µg)

• Purity:

  > 98% by SDS-PAGE & HPLC analyses

• Bioactivity:

  Testing in progress.

• Length:

  256

• Form:

  Lyophilized

• Molecular Weight:

  26.4 kDa

• Host or Source:

  E. coli